Keywords: Biogen Idec, Facet Biotech, M&A, volociximab, daclizumab

Biogen Idec ups offer 21% for Facet Biotech to $17.50 a share, which is again rejected by board

Article | 04 December 2009

Print This

US biotechnology firm Biogen Idec is continuing its fight to gain control of Facet Biotech, increasing its offer to $17.50 per ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in